RxDoctor Payments Data

Artem Kaplan

Neurology · New York, NYNPI 1477808590

Payments from drug & device makers

$201,268in general payments, 2019–2025

Across 944 payments — averaging $213.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$77K
  • Biohaven Pharmaceutical Holding Company Ltd.$67K
  • Ipsen Pharma SAS$17K
  • SK Life Science, Inc.$16K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
  • AbbVie$6K
  • plus $8K from 48 others
$21,186in research payments, 2019–2025

Across 14 payments — averaging $1513.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$21K

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$15,88199%
  • Education$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$201,268 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$1,012,576
Medicare patients
296
Services billed
114,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$272,414
UbrelvyUbrogepant16$17,677
Nurtec OdtRimegepant Sulfate11$17,180
Ajovy AutoinjectorFremanezumab-Vfrm11$12,906
Emgality PenGalcanezumab-Gnlm11$7,358
Carbidopa12$4,789
Gabapentin144$2,262
Sertraline Hcl14$1,380
Sumatriptan Succinate53$677
Escitalopram Oxalate76$613
Carbidopa-LevodopaCarbidopa/Levodopa46$474
RizatriptanRizatriptan Benzoate33$373
Clonazepam16$330
Trazodone Hcl23$170
Duloxetine Hcl11$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$76,705$289,59523 claims
AbbVieUbrelvy$6,379$17,67716 claims
Almatica Pharma LLCSertraline Hcl$88$1,38014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →